LYON, France, May 28, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 -- June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We look forward to showcasing our minimally invasive technologies to the global urology audience. We will take this opportunity to present four abstracts that outline our long-term positive European experience utilizing our HIFU treatment of localized prostate cancer. Our team of experts from France, Germany and the US will highlight positive Ablatherm-HIFU results obtained with patients who underwent HIFU as primary care or as a salvage treatment after radiotherapy failure or hormone-therapy failure. Our strong European patient database registry is proving to be a supportive tool to compile these positive results and assist in validating Ablatherm-HIFU's effectiveness. Two separate abstracts addressing our lithotripsy technology for urinary stones will also be presented at the AUA."

Mr. Oczachowski, continued, "I am very pleased to invite and welcome all urologists, partners and investors to visit EDAP's team at our booth to discuss our technologies and strategies further."

The Annual Scientific Meeting of the American Urological Association (AUA) is the largest meeting of urologic professionals in the world. More than 15,000 urologists, healthcare professionals, exhibitors and media attend this meeting each year.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

CONTACT:  EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX